克罗恩病：初诊
Crohn's disease: the first visit.
作者信息
Di Palma Jack A, Farraye Francis A
机构信息
Dr. Di Palma is a Professor of Medicine and Director of the Division of Gastroenterology at the University of South Alabama College of Medicine in Mobile, Alabama.
出版信息
Gastroenterol Hepatol (N Y). 2011 Mar;7(3):163-9.
Abstract
A Crohn's disease patient's first visit to a new practice is the optimal time to collect important clinical data and identify appropriate therapies. A methodologic approach to this visit is crucial. The focus of this visit should be on preparing the patient for the initiation of treatment, with particular attention to the necessary steps prior to the use of immunosuppressive and biologic agents. This paper is intended to provide recommendations and a checklist for the initial assessment and evaluation of patients with Crohn's disease.
摘要
克罗恩病患者首次就诊新诊所是收集重要临床数据并确定合适治疗方法的最佳时机。对此就诊采用一种方法学途径至关重要。此次就诊的重点应是让患者为开始治疗做好准备，尤其要关注使用免疫抑制和生物制剂之前的必要步骤。本文旨在为克罗恩病患者的初始评估和评价提供建议及清单。
相似文献
1
Crohn's disease: the first visit.
Gastroenterol Hepatol (N Y). 2011 Mar;7(3):163-9.
2
Crohn's disease: the subsequent visit.
Gastroenterol Hepatol (N Y). 2013 Jan;9(1):16-20.
3
Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study.
United European Gastroenterol J. 2016 Dec;4(6):784-793. doi: 10.1177/2050640615600116. Epub 2015 Aug 6.
4
Anoperineal lesions in Crohn's disease: French recommendations for clinical practice.
Tech Coloproctol. 2017 Sep;21(9):683-691. doi: 10.1007/s10151-017-1684-y. Epub 2017 Sep 19.
5
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
6
[Anti-TNF therapy in treatment of luminal Crohn's disease].
Acta Med Croatica. 2013 Apr;67(2):179-89.
7
Optimising monitoring in the management of Crohn's disease: a physician's perspective.
J Crohns Colitis. 2013 Sep;7(8):653-69. doi: 10.1016/j.crohns.2013.02.005. Epub 2013 Apr 4.
8
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients.
Gastroenterol Hepatol. 2018 Feb;41(2):118-127. doi: 10.1016/j.gastrohep.2017.10.003. Epub 2017 Dec 21.
9
Natalizumab for induction of remission in Crohn's disease.
Cochrane Database Syst Rev. 2006 Jul 19(3):CD006097. doi: 10.1002/14651858.CD006097.
10
Natalizumab for induction of remission in Crohn's disease.
Cochrane Database Syst Rev. 2007 Jan 24(1):CD006097. doi: 10.1002/14651858.CD006097.pub2.
引用本文的文献
1
Culture-based characterization of gut microbiota in inflammatory bowel disease.
Front Microbiol. 2025 Feb 20;16:1538620. doi: 10.3389/fmicb.2025.1538620. eCollection 2025.
2
Phylogenetic and pathotype analysis of stool isolates from Egyptian patients with inflammatory bowel disease.
Germs. 2019 Dec 2;9(4):172-181. doi: 10.18683/germs.2019.1173. eCollection 2019 Dec.
3
Vaccinating Patients With Inflammatory Bowel Disease.
Gastroenterol Hepatol (N Y). 2016 Sep;12(9):540-546.
4
Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines.
Ann Gastroenterol. 2015 Oct-Dec;28(4):417-25.
5
Health maintenance and inflammatory bowel disease.
Curr Gastroenterol Rep. 2014 Oct;16(10):402. doi: 10.1007/s11894-014-0402-4.
6
Crohn's disease: the subsequent visit.
Gastroenterol Hepatol (N Y). 2013 Jan;9(1):16-20.
本文引用的文献
1
Optimising use of thiopurines in inflammatory bowel disease.
Frontline Gastroenterol. 2010 Apr;1(1):44-51. doi: 10.1136/fg.2009.000174. Epub 2010 Apr 1.
2
Serologic Markers in the Diagnosis and Management of IBD.
Gastroenterol Hepatol (N Y). 2007 Jun;3(6):424-6.
3
Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge.
Inflamm Bowel Dis. 2011 Dec;17(12):2536-40. doi: 10.1002/ibd.21667. Epub 2011 Apr 28.
4
Emerging prognostic markers to determine Crohn's disease natural history and improve management strategies: a review of recent literature.
Gastroenterol Hepatol (N Y). 2010 Feb;6(2):99-107.
5
Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.
World J Gastroenterol. 2010 Jun 7;16(21):2604-8. doi: 10.3748/wjg.v16.i21.2604.
6
A practical guide to vaccinating the inflammatory bowel disease patient.
Am J Gastroenterol. 2010 Jun;105(6):1231-8. doi: 10.1038/ajg.2009.733. Epub 2010 Jan 26.
7
Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity.
Clin Gastroenterol Hepatol. 2010 Apr;8(4):357-63. doi: 10.1016/j.cgh.2010.01.001. Epub 2010 Jan 21.
8
Recommended adult immunization schedule: United States, 2010.
Ann Intern Med. 2010 Jan 5;152(1):36-9. doi: 10.7326/0003-4819-152-1-201001050-00008.
9
Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Am J Gastroenterol. 2010 Jan;105(1):162-9. doi: 10.1038/ajg.2009.545. Epub 2009 Sep 15.
10
Biological therapies for inflammatory bowel diseases.
Gastroenterology. 2009 Apr;136(4):1182-97. doi: 10.1053/j.gastro.2009.02.001. Epub 2009 Feb 26.
Zotero 插件